Korean Journal of Radiology

The Korean Society of Radiology (대한영상의학회)
권호 표지
DOI QR코드

DOI QR Code

Single-Dose Gadoterate Meglumine for 3T Late Gadolinium Enhancement MRI for the Assessment of Chronic Myocardial Infarction: Intra-Individual Comparison with Conventional Double-Dose 1.5T MRI

  • Lim, Jiyeon (Department of Radiology, Seoul National University Hospital) ;
  • Park, Eun-Ah (Department of Radiology, Seoul National University Hospital) ;
  • Song, Yong Sub (Department of Radiology, Seoul National University Hospital) ;
  • Lee, Whal (Department of Radiology, Seoul National University Hospital)
  • Received : 2017.07.03
  • Accepted : 2017.11.01
  • Published : 2018.06.01
⟨ Previous Next ⟩

Abstract

Objective: To intra-individually compare 3T magnetic resonance (MR) images obtained with one dose gadoterate meglumine to 1.5T MR using conventional double dose for assessment of chronic myocardial infarction. Materials and Methods: Sixteen patients diagnosed with chronic myocardial infarctions were examined on single-dose 3T MR within two weeks after undergoing double-dose 1.5T MR. Representative short-axis images were acquired at three points after administration of gadoterate meglumine. Contrast-to-noise ratios between infarcted and normal myocardium ($CNR_{infarct-normal}$) and between infarct and left ventricular cavity ($CNR_{infarct-LVC}$) were calculated and compared intra-individually at each temporal scan. Additionally, two independent readers assessed relative infarct size semi-automatically and inter-observer reproducibility was evaluated using intraclass correlation coefficient. Results: While higher $CNR_{infarct-normal}$ was revealed at single-dose 3T at only 10 minutes scan (p = 0.047), the $CNR_{infarct-LVC}$ was higher at single-dose 3T MR at each temporal scan (all, p < 0.05). Measurement of relative infarct size was not significantly different between both examinations for both observers (all, p > 0.05). However, inter-observer reproducibility was higher at single-dose 3T MR (all, p < 0.05). Conclusion: Single-dose 3T MR is as effective as double-dose 1.5T MR for delineation of infarcted myocardium while being superior in detection of infarcted myocardium from the blood cavity, and provides better reproducibility for infarct size quantification.

Keywords

Acknowledgement

Supported by : Dong-Kook Pharmaceutical

References

  1. Kim RJ, Shah DJ, Judd RM. How we perform delayed enhancement imaging. J Cardiovasc Magn Reson 2003;5:505-514 https://doi.org/10.1081/JCMR-120022267
  2. Kim RJ, Wu E, Rafael A, Chen EL, Parker MA, Simonetti O, et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med 2000;343:1445-1453 https://doi.org/10.1056/NEJM200011163432003
  3. Kim RJ, Fieno DS, Parrish TB, Harris K, Chen EL, Simonetti O, et al. Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation 1999;100:1992-2002 https://doi.org/10.1161/01.CIR.100.19.1992
  4. Nacif MS, Arai AE, Lima JA, Bluemke DA. Gadoliniumenhanced cardiovascular magnetic resonance: administered dose in relationship to United States Food and Drug Administration (FDA) guidelines. J Cardiovasc Magn Reson 2012;14:18
  5. Cowper SE. Nephrogenic fibrosing dermopathy: the first 6 years. Curr Opin Rheumatol 2003;15:785-790 https://doi.org/10.1097/00002281-200311000-00017
  6. Thomsen HS, Marckmann P, Logager VB. Nephrogenic systemic fibrosis (NSF): a late adverse reaction to some of the gadolinium based contrast agents. Cancer Imaging 2007;7:130-137 https://doi.org/10.1102/1470-7330.2007.0019
  7. Scheinfeld N. Nephrogenic fibrosing dermopathy: a comprehensive review for the dermatologist. Am J Clin Dermatol 2006;7:237-247 https://doi.org/10.2165/00128071-200607040-00005
  8. Farrelly C, Rehwald W, Salerno M, Davarpanah A, Keeling AN, Jacobson JT, et al. Improved detection of subendocardial hyperenhancement in myocardial infarction using dark blood-pool delayed enhancement MRI. AJR Am J Roentgenol 2011;196:339-348 https://doi.org/10.2214/AJR.10.4418
  9. Wieben O, Francois C, Reeder SB. Cardiac MRI of ischemic heart disease at 3 T: potential and challenges. Eur J Radiol 2008;65:15-28 https://doi.org/10.1016/j.ejrad.2007.10.022
  10. Klumpp B, Fenchel M, Hoevelborn T, Helber U, Scheule A, Claussen C, et al. Assessment of myocardial viability using delayed enhancement magnetic resonance imaging at 3.0 Tesla. Invest Radiol 2006;41:661-667 https://doi.org/10.1097/01.rli.0000233321.82194.09
  11. Haacke EM, Brown RW, Thompson MR, Venkatesan R. Magnetic resonance imaging: physical principles and sequence design, 1st ed. New Jersey: John Wiley & Sons, 1999
  12. Bottomley PA, Foster TH, Argersinger RE, Pfeifer LM. A review of normal tissue hydrogen NMR relaxation times and relaxation mechanisms from 1-100 MHz: dependence on tissue type, NMR frequency, temperature, species, excision, and age. Med Phys 1984;11:425-448 https://doi.org/10.1118/1.595535
  13. Cheng AS, Robson MD, Neubauer S, Selvanayagam JB. Irreversible myocardial injury: assessment with cardiovascular delayed-enhancement MR imaging and comparison of 1.5 and 3.0 T--initial experience. Radiology 2007;242:735-742 https://doi.org/10.1148/radiol.2423060299
  14. Flett AS, Hasleton J, Cook C, Hausenloy D, Quarta G, Ariti C, et al. Evaluation of techniques for the quantification of myocardial scar of differing etiology using cardiac magnetic resonance. JACC Cardiovasc Imaging 2011;4:150-156 https://doi.org/10.1016/j.jcmg.2010.11.015
  15. De Cobelli F, Esposito A, Perseghin G, Sallemi C, Belloni E, Ravelli S, et al. Intraindividual comparison of gadobutrol and gadopentetate dimeglumine for detection of myocardial late enhancement in cardiac MRI. AJR Am J Roentgenol 2012;198:809-816 https://doi.org/10.2214/AJR.11.7118
  16. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33:159-174 https://doi.org/10.2307/2529310
  17. Kramer U, Fenchel M, Laub G, Seeger A, Klumpp B, Bretschneider C, et al. Low-dose, time-resolved, contrastenhanced 3D MR angiography in the assessment of the abdominal aorta and its major branches at 3 Tesla. Acad Radiol 2010;17:564-576 https://doi.org/10.1016/j.acra.2009.12.011
  18. Herborn CU, Runge VM, Watkins DM, Gendron JM, Naul LG. MR angiography of the renal arteries: intraindividual comparison of double-dose contrast enhancement at 1.5 T with standard dose at 3 T. AJR Am J Roentgenol 2008;190:173-177 https://doi.org/10.2214/AJR.07.2486
  19. Fratz S, Chung T, Greil GF, Samyn MM, Taylor AM, Valsangiacomo Buechel ER, et al. Guidelines and protocols for cardiovascular magnetic resonance in children and adults with congenital heart disease: SCMR expert consensus group on congenital heart disease. J Cardiovasc Magn Reson 2013;15:51 https://doi.org/10.1186/1532-429X-15-51
  20. Kellman P, Arai AE, McVeigh ER, Aletras AH. Phase-sensitive inversion recovery for detecting myocardial infarction using gadolinium-delayed hyperenhancement. Magn Reson Med 2002;47:372-383 https://doi.org/10.1002/mrm.10051
  21. Idee JM, Port M, Raynal I, Schaefer M, Le Greneur S, Corot C. Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review. Fundam Clin Pharmacol 2006;20:563-576 https://doi.org/10.1111/j.1472-8206.2006.00447.x
  22. Ishiguchi T, Takahashi S. Safety of gadoterate meglumine (Gd-DOTA) as a contrast agent for magnetic resonance imaging: results of a post-marketing surveillance study in Japan. Drugs R D 2010;10:133-145 https://doi.org/10.2165/11539140-000000000-00000
  23. Deray G, Rouviere O, Bacigalupo L, Maes B, Hannedouche T, Vrtovsnik F, et al. Safety of meglumine gadoterate (Gd-DOTA)-enhanced MRI compared to unenhanced MRI in patients with chronic kidney disease (RESCUE study). Eur Radiol 2013;23:1250-1259 https://doi.org/10.1007/s00330-012-2705-x
  24. Wagner M, Schilling R, Doeblin P, Huppertz A, Luhur R, Schwenke C, et al. Macrocyclic contrast agents for magnetic resonance imaging of chronic myocardial infarction: intraindividual comparison of gadobutrol and gadoterate meglumine. Eur Radiol 2013;23:108-114 https://doi.org/10.1007/s00330-012-2563-6
  25. Kim YK, Park EA, Lee W, Kim SY, Chung JW. Late gadolinium enhancement magnetic resonance imaging for the assessment of myocardial infarction: comparison of image quality between single and double doses of contrast agents. Int J Cardiovasc Imaging 2014;30 Suppl 2:129-135
  26. Kim HW, Rehwald WG, Wendell DC, Jenista E, Assche LV, Jensen CJ, et al. Flow-Independent Dark-blood DeLayed Enhancement (FIDDLE): validation of a novel black blood technique for the diagnosis of myocardial infarction. J Cardiovasc Magn Reson 2016;18(Suppl 1):O55 https://doi.org/10.1186/1532-429X-18-S1-O55
  27. Peel SA, Morton G, Chiribiri A, Schuster A, Nagel E, Botnar RM. Dual inversion-recovery mr imaging sequence for reduced blood signal on late gadolinium-enhanced images of myocardial scar. Radiology 2012;264:242-249 https://doi.org/10.1148/radiol.12112004
  28. Secchi F, Di Leo G, Papini GD, Giacomazzi F, Di Donato M, Sardanelli F. Optimizing dose and administration regimen of a high-relaxivity contrast agent for myocardial MRI late gadolinium enhancement. Eur J Radiol 2011;80:96-102 https://doi.org/10.1016/j.ejrad.2010.06.040

Cited by

  1. Guidelines for Cardiovascular Magnetic Resonance Imaging from the Korean Society of Cardiovascular Imaging-Part 3: Perfusion, Delayed Enhancement, and T1- and T2 Mapping vol.20, pp.12, 2018, https://doi.org/10.3348/kjr.2019.0411
  2. Guideline for Cardiovascular Magnetic Resonance Imaging from the Korean Society of Cardiovascular Imaging-Part 1: Standardized Protocol vol.3, pp.3, 2018, https://doi.org/10.22468/cvia.2019.00108
  3. Guideline for Cardiovascular Magnetic Resonance Imaging from the Korean Society of Cardiovascular Imaging-Part 1: Standardized Protocol vol.20, pp.9, 2018, https://doi.org/10.3348/kjr.2019.0398
  4. Guidelines for Cardiovascular Magnetic Resonance Imaging from the Korean Society of Cardiovascular Imaging-Part 2: Interpretation of Cine, Flow, and Angiography Data vol.3, pp.4, 2019, https://doi.org/10.22468/cvia.2019.00115
  5. Guidelines for Cardiovascular Magnetic Resonance Imaging from the Korean Society of Cardiovascular Imaging-Part 2: Interpretation of Cine, Flow, and Angiography Data vol.20, pp.11, 2019, https://doi.org/10.3348/kjr.2019.0407
  6. Guidelines for Cardiovascular Magnetic Resonance Imaging from Korean Society of Cardiovascular Imaging (KOSCI) - Part 1: Standardized Protocol vol.23, pp.4, 2018, https://doi.org/10.13104/imri.2019.23.4.296
  7. Guidelines for Cardiovascular Magnetic Resonance Imaging from the Korean Society of Cardiovascular Imaging (KOSCI) - Part 2: Interpretation of Cine, Flow, and Angiography Data vol.23, pp.4, 2018, https://doi.org/10.13104/imri.2019.23.4.316
  8. Guidelines for Cardiovascular Magnetic Resonance Imaging from the Korean Society of Cardiovascular Imaging-Part 3: Perfusion, Delayed Enhancement, and T1- and T2 Mapping vol.4, pp.1, 2018, https://doi.org/10.22468/cvia.2019.00171
  9. Guidelines for Cardiovascular Magnetic Resonance Imaging from the Korean Society of Cardiovascular Imaging (KOSCI) - Part 3: Perfusion, Delayed Enhancement, and T1- and T2 Mapping vol.24, pp.1, 2018, https://doi.org/10.13104/imri.2020.24.1.1